<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01056107</url>
  </required_header>
  <id_info>
    <org_study_id>09-005871</org_study_id>
    <secondary_id>UL1RR024150</secondary_id>
    <nct_id>NCT01056107</nct_id>
  </id_info>
  <brief_title>Effects of ROSE-010 on GI Transit in Constipation Predominant Irritable Bowel Syndrome (C-IBS) Patients</brief_title>
  <official_title>Effect of ROSE-010 on Gastrointestinal Motor Functions in Female Patients With Constipation Predominant Irritable Bowel Syndrome (C-IBS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rose Pharma A/S</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Center for Research Resources (NCRR)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial will study the effects of an investigational (not FDA approved) medication,
      ROSE-010, on the movement of food through the stomach, small intestine and colon in females
      with constipation predominant irritable bowel syndrome (C-IBS).

      The study hypothesis is that ROSE-010 will delay gastric emptying of solids and enhances
      gastric accommodation without retarding colonic transit in female patients with C-IBS.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Methodology

      Female patients with C-IBS will be screened for eligibility and informed about the study at
      the initial screening visit Visit 1. Within two weeks of Visit 1, eligible patients will be
      randomized to study medication, either 30 mcg, 100 mcg or 300 mcg ROSE-010 or placebo
      administered via abdominal subcutaneous (s.c.) injection for a total of four days, three
      consecutive days during transit scintigraphy and once prior to SPECT imaging. The allocation
      to treatment group will be concealed.

      Study medication will be administered at Visits 2, 3, and 4, the days of scintigraphic
      assessment of gastric, small bowel and colonic transit of solids performed over a 48 hour
      period.

      Within two to seven days of Visit 4, patients will be instructed to return for administration
      of a final injection of study medication followed by SPECT gastric accommodation measurements
      (Visit 5). Within seven to ten days of Visit 5, patients will return for Visit 6, final
      safety monitoring and an exit interview with study staff.

      Investigational product, dosage and mode of administration

      Patients will receive placebo or 30 mcg, 100 mcg or 300 mcg ROSE-010 administered s.c. in the
      abdomen once on Visit 2, immediately before the standardized breakfast meal, fifteen minutes
      before the first camera image is obtained. Study medication will be administered fifteen
      minutes before camera images obtained on Visits 3 and 4. Study medication will be
      administered immediately after the first fasting scan is obtained and before the second
      fasting scan during SPECT at Visit 5.

      Duration of treatment

      ROSE-010 or matching placebo will be administered via abdominal s.c injection once daily for
      three consecutive days and one final day two to seven days later, over a ten-day interval.

      Duration of patients involvement in the study

      Each patient will attend six visits at the clinic during a period of two to four weeks.

      Efficacy assessments

        1. Scintigraphic gastrointestinal and colonic transit

        2. Technetium-99m (99mTc) SPECT measurement of gastric volumes

        3. Assessment of stool frequency and consistency made by the patient using the Bowel
           Pattern Diary

      Safety assessments

      The following safety assessments will be performed:

        1. Laboratory safety tests, including a complete blood count (CBC), a comprehensive
           metabolic panel (CMP), and urinalysis (UA) at Visit 1 (study entry) and Visit 6 (study
           exit)

        2. A physical examination by a study physician at Visit 1

        3. Weight and vital signs (including temperature, pulse, blood pressure and respiration
           rate) at every visit

        4. Urine pregnancy tests performed at Visit 1 and within 48 hours prior to receipt of
           radiation at Visit 2 transit test and Visit 5 SPECT test

        5. Interview for concomitant medications and adverse events at every visit

      Statistical methods

      An analysis of covariance (ANCOVA) will be used to compare transit parameters and gastric
      volumes among the treatment groups. If necessary a suitable transformation for potential
      skewness in the distributions of measured volumes may be used (e.g., ANCOVA on ranks or log
      volumes). If ANCOVA shows a p value less than or equal to 0.10, then both the 100 mcg and 300
      mcg doses will be compared to placebo (p value less than or equal to 0.25). Dunnett's Test
      will be used to compare each dose group with placebo. Since each of the primary endpoints
      assesses a separate hypothesis regarding the effects of ROSE-010, no adjustment in the alpha
      level for testing multiple types of endpoints is anticipated, and a two-sided significance
      level of 0.05 will be used in each ANCOVA model.

      Analysis data sets

      The primary analyses will follow the intent to treat (ITT) paradigm with all patients
      randomized included in the analyses. Those patients with missing response values will have
      their missing values imputed via the overall (patients with non-missing data) mean and a
      corresponding adjustment in the ANCOVA residual error variance degrees of freedom
      (subtracting one for each missing value imputed). Safety data will be presented for all
      patients receiving investigational product.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Colonic Transit, Colonic Geometric Center at 24 Hours</measure>
    <time_frame>24 hours (Visit 3 = Day 1)</time_frame>
    <description>The scintigraphic method is used to measure colonic transit. An isotope is adsorbed on activated charcoal particles and delivered to the colon in a delayed release capsule. Anterior and posterior gamma images are taken hourly. The geometric center (GC) is the weighted average of counts in the different colonic regions. The scale ranges from 1 to 5; a high GC implies faster colonic transit, a GC of 1 implies all isotope is in the ascending colon, and a GC of 5 implies all isotope is in the stool.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change Between Postprandial and Fasting Whole Gastric Volume by Technetium-99m (99mTc)-SPECT Imaging (Gastric Accommodation)</measure>
    <time_frame>approximately 1 hour after 99mTC injection, approximately 30 min after liquid meal (Visit 5 = approximately 2-10 days after Visit 4)</time_frame>
    <description>A noninvasive SPECT method was used to measure gastric volume during fasting and 32 min after a liquid nutritional supplement meal. Subjects reported to the clinic after an overnight fast. 99mTC was giving by an intravenous injection in the forearm. The first fasting scan was obtained, and the study medication was given s.c. After 10 min, a 2nd fasting post medication scan was obtained, and the meal consumed; then two serial postprandial scans were obtained. Each scan required 9-12 min. Tomographic images of the gastric wall were obtained throughout the long axis of the stomach using a dual-head gamma camera that rotates around the body. This allows assessment of the radiolabeled circumference of the gastric wall, rather than the intragastric content. For this outcome measure, the scans for the &quot;fasting volume&quot; and 2 &quot;postprandial volumes&quot; were used. The 2 postprandial (PP) volumes were averaged. Change was calculated as (PP - Fasting = gastric accommodation).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Half Time (t1/2) of Gastric Emptying of Solids Measured by Scintigraphy (Gastric Transit)</measure>
    <time_frame>approximately 2 hours after radiolabeled meal is ingested (Visit 2 = Day 0)</time_frame>
    <description>Half time (t1/2) of gastric emptying (GE) of solids is the time for half of the ingested solids or liquids to leave the stomach. The scintigraphy for GE t1/2 was done on Visit 2 (Day 0 of the study), the first day of scintigraphy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gastric Residual at 2 and 4 Hours Measured by Scintigraphy</measure>
    <time_frame>2 hours, 4 hours (Visit 2 = Day 0)</time_frame>
    <description>The gastric residual will be calculated as the proportion of isotope remaining in the stomach (at 2 and 4 hours).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Colonic Geometric Center at 4 h Measured by Scintigraphy</measure>
    <time_frame>4 hours (Visit 2 = Day 0)</time_frame>
    <description>The scintigraphic method is used to measure colonic transit. An isotope is adsorbed on activated charcoal particles and delivered to the colon in a delayed release capsule. Anterior and posterior gamma images are taken hourly. The geometric center (GC) is the weighted average of counts in the different colonic regions. The scale ranges from 1 to 5; a high GC implies faster colonic transit, a GC of 1 implies all isotope is in the ascending colon, and a GC of 5 implies all isotope is in the stool. (Note: when there is no radio isotope in the colon (e.g., at 4 hours) the geometric center values are recorded as &quot;zero,&quot; thus the mean values can be less than one.)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Colonic Filling at 6 h Measured by Scintigraphy</measure>
    <time_frame>6 hours (Visit 2 = Day 0)</time_frame>
    <description>Percent of the radio-labeled meal that reached the colon at 6 hours, indirectly reflecting small bowel transit time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ascending Colon Emptying Half-time (AC t1/2) Measured by Scintigraphy</measure>
    <time_frame>48 hours (Visit 4 = Day 2)</time_frame>
    <description>Ascending colon emptying half-time will be estimated by power exponential analysis of the proportionate emptying over time of counts from the colon. The primary data for this analysis will be the proportion of decay and depth-corrected counts in the ascending colon on the hourly scans on the first day of transit measurement and the 48 hour data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Colonic Transit, Colonic Geometric Center at 48 h Measured by Scintigraphy, as Compared to Placebo.</measure>
    <time_frame>48 hours (Visit 4 = Day 2)</time_frame>
    <description>The scintigraphic method is used to measure colonic transit. An isotope is adsorbed on activated charcoal particles and delivered to the colon in a delayed release capsule. Anterior and posterior gamma images are taken hourly. The geometric center (GC) is the weighted average of counts in the different colonic regions. The scale ranges from 1 to 5; a high GC implies faster colonic transit, a GC of 1 implies all isotope is in the ascending colon, and a GC of 5 implies all isotope is in the stool.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stool Frequency</measure>
    <time_frame>screening visit (Visit 1), 34 days (Visit 6)</time_frame>
    <description>Stool frequency was self reported in a Bowel Pattern Diary. The bowel pattern diary was dispensed at the screening visit, and the completed bowel pattern diary was collected at the completion of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stool Consistency Post Treatment</measure>
    <time_frame>34 days (Visit 6)</time_frame>
    <description>The subjects rated their stool consistency using the 7-point Bristol Stool Scale. The Bristol Stool Scale is a medical aid designed to classify the form of human feces into seven categories or types. Types 1 and 2 indicate constipation with 3 and 4 being the &quot;ideal stools&quot; especially the latter, as they are the easiest to defecate, and 5-7 tending towards diarrhea. The Bristol stool form was part of the bowel pattern diary, which was dispensed at the screening visit, and the completed bowel pattern diary was collected at the completion of the study.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Irritable Bowel Syndrome Constipation Predominant</condition>
  <arm_group>
    <arm_group_label>ROSE-010 30 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A glucagon-like peptide-1 (GLP-1) analogue. Subjects received a ROSE-010 30 mcg subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ROSE-010 100 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A glucagon-like peptide-1 (GLP-1) analogue. Subjects received a ROSE-010 100 mcg subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ROSE-010 300 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A glucagon-like peptide-1 (GLP-1) analogue. A glucagon-like peptide-1 (GLP-1) analogue. Subjects received a ROSE-010 300 mcg subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects received a matching placebo subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ROSE-010</intervention_name>
    <description>The study medication was used in 30 mcg, 100 mcg, and 300 mcg subcutaneous injections daily, depending upon study arm.</description>
    <arm_group_label>ROSE-010 30 mcg</arm_group_label>
    <arm_group_label>ROSE-010 100 mcg</arm_group_label>
    <arm_group_label>ROSE-010 300 mcg</arm_group_label>
    <other_name>Glucagon-like peptide-1 (GLP-1) analogue</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo subcutaneous injection daily</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Glucagon-like peptide-1 (GLP-1) analogue</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Female aged 18-65 years old inclusive.

          2. A previous diagnosis of IBS according to Rome III criteria to include those patients
             who have had recurrent abdominal pain or discomfort for the at least the six months
             prior to diagnosis and currently at least three days per month in the last three
             months associated with two or more of the following:

               1. improvement with defecation

               2. onset associated with a change in the frequency of stool

               3. onset associated with a change in form (appearance) of stool.

          3. Constipation predominant type IBS as defined by one or more of the following:

               1. fewer than three spontaneous complete bowel movements per week

               2. hard or lumpy stools more than 25% of the time

               3. straining during a bowel movement more than 25% of the time.

          4. A normal rectal exam result on file within the past two years or performed at screen
             to exclude the possibility of an evacuation disorder. Examination must exclude
             findings suggestive of an evacuation disorder such as high sphincter tone at rest,
             failure of perineal descent by more than one centimeter on straining and last, spasm,
             tenderness or paradoxical contraction of the puborectalis muscles.

          5. Females of child bearing potential (those who have not experienced a bilateral tubal
             ligation, hysterectomy or menopause) must use an acceptable method of contraception
             during the study. Acceptable methods are surgical sterilization, hormonal methods such
             as oral contraceptives, Norplant and Depo-Provera, double barrier method such as a
             condom and spermicide, and an intrauterine device (IUD). Abstinent females may
             participate if they agree to use the double barrier method should they become sexually
             active during the study.

          6. Able to provide written informed consent prior to any study procedures being
             performed.

        Exclusion Criteria:

          1. Female patients who are pregnant or breast-feeding.

          2. Structural or metabolic diseases/conditions that affect the gastrointestinal system,
             or functional gastrointestinal disorders other than C-IBS.

          3. Unable to withdraw medications 48 hours prior to the study: any medication that alters
             GI transit including but not limited to laxatives, magnesium or aluminum-containing
             antacids, prokinetics, erythromycin, narcotics, anticholinergics, tricyclic
             antidepressants and serotonin-norepinephrine reuptake inhibitors (SNRIs); analgesic
             drugs including opiates, nonsteroidal anti-inflammatory drugs (NSAIDs), and COX 2
             inhibitors (Note: Tylenol is permitted), GABAergic agents and benzodiazepines. Note:
             All other concomitant medications will be reviewed on a case by case basis by the
             study physicians.

          4. Clinical evidence (including but not limited to a clinically significant abnormal
             physical exam, ECG or laboratory result in the past medical record) or current
             clinically significant abnormal physical exam or laboratory test result that could
             indicate significant cardiovascular, respiratory, renal, hepatic, gastrointestinal,
             hematological, neurological, psychiatric, or other diseases that interfere with the
             objectives of the study. If a laboratory test result is abnormal and clinically
             significant, it may be repeated once at the discretion of the PI. If the laboratory
             test result remains abnormal and clinically significant, the patient will be referred
             to a primary care physician for further evaluation.

          5. Patients who are considered by the Investigator to be alcoholics not in remission or
             known substance abusers.

          6. Patients who have participated in another clinical study within the past 30 days.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Camilleri, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Camilleri M, Vazquez-Roque M, Iturrino J, Boldingh A, Burton D, McKinzie S, Wong BS, Rao AS, Kenny E, MÃ¥nsson M, Zinsmeister AR. Effect of a glucagon-like peptide 1 analog, ROSE-010, on GI motor functions in female patients with constipation-predominant irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol. 2012 Jul;303(1):G120-8. doi: 10.1152/ajpgi.00076.2012. Epub 2012 Apr 19.</citation>
    <PMID>22517769</PMID>
  </results_reference>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 22, 2010</study_first_submitted>
  <study_first_submitted_qc>January 25, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2010</study_first_posted>
  <results_first_submitted>February 21, 2013</results_first_submitted>
  <results_first_submitted_qc>April 24, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 31, 2013</results_first_posted>
  <last_update_submitted>April 24, 2013</last_update_submitted>
  <last_update_submitted_qc>April 24, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 31, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Michael Camilleri</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Constipation, Irritable Bowel Syndrome (IBS), Glucagon Like Peptide analogue</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Constipation</mesh_term>
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucagon</mesh_term>
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited at the Mayo Clinic in Rochester, Minnesota.</recruitment_details>
      <pre_assignment_details>52 subjects were enrolled, but 6 subjects were excluded because they did not meet eligibility criteria.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>ROSE-010 30 Mcg</title>
          <description>A glucagon-like peptide-1 (GLP-1) analogue. Subjects received a ROSE-010 30 mcg subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.</description>
        </group>
        <group group_id="P2">
          <title>ROSE-010 100 Mcg</title>
          <description>A glucagon-like peptide-1 (GLP-1) analogue. Subjects received a ROSE-010 100 mcg subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.</description>
        </group>
        <group group_id="P3">
          <title>ROSE-010 300 Mcg</title>
          <description>A glucagon-like peptide-1 (GLP-1) analogue. Subjects received a ROSE-010 300 mcg subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>Subjects received a matching placebo subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ROSE-010 30 Mcg</title>
          <description>A glucagon-like peptide-1 (GLP-1) analogue. Subjects received a ROSE-010 30 mcg subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.</description>
        </group>
        <group group_id="B2">
          <title>ROSE-010 100 Mcg</title>
          <description>A glucagon-like peptide-1 (GLP-1) analogue. Subjects received a ROSE-010 100 mcg subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.</description>
        </group>
        <group group_id="B3">
          <title>ROSE-010 300 Mcg</title>
          <description>A glucagon-like peptide-1 (GLP-1) analogue. Subjects received a ROSE-010 300 mcg subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>Subjects received a matching placebo subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="12"/>
            <count group_id="B4" value="12"/>
            <count group_id="B5" value="46"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.4" spread="6.0"/>
                    <measurement group_id="B2" value="40.2" spread="11.7"/>
                    <measurement group_id="B3" value="42.0" spread="11.9"/>
                    <measurement group_id="B4" value="43.8" spread="8.0"/>
                    <measurement group_id="B5" value="42.4" spread="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.2" spread="3.8"/>
                    <measurement group_id="B2" value="26.4" spread="5.5"/>
                    <measurement group_id="B3" value="26.4" spread="4.8"/>
                    <measurement group_id="B4" value="27.7" spread="4.0"/>
                    <measurement group_id="B5" value="26.9" spread="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Stool frequency</title>
          <units>Stools/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.7" spread="0.3"/>
                    <measurement group_id="B2" value="1.0" spread="0.8"/>
                    <measurement group_id="B3" value="0.8" spread="0.6"/>
                    <measurement group_id="B4" value="0.7" spread="0.4"/>
                    <measurement group_id="B5" value="0.8" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Stool Consistency</title>
          <description>The subjects rated their stool consistency using the Bristol Stool Scale. The Bristol Stool Scale is a medical aid designed to classify the form of human feces into seven categories or types. Types 1 and 2 indicate constipation with 3 and 4 being the &quot;ideal stools&quot; especially the latter, as they are the easiest to defecate, and 5-7 tending towards diarrhea.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.8" spread="1.1"/>
                    <measurement group_id="B2" value="3.0" spread="0.8"/>
                    <measurement group_id="B3" value="2.8" spread="1.8"/>
                    <measurement group_id="B4" value="2.4" spread="0.9"/>
                    <measurement group_id="B5" value="2.7" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Colonic Transit, Colonic Geometric Center at 24 Hours</title>
        <description>The scintigraphic method is used to measure colonic transit. An isotope is adsorbed on activated charcoal particles and delivered to the colon in a delayed release capsule. Anterior and posterior gamma images are taken hourly. The geometric center (GC) is the weighted average of counts in the different colonic regions. The scale ranges from 1 to 5; a high GC implies faster colonic transit, a GC of 1 implies all isotope is in the ascending colon, and a GC of 5 implies all isotope is in the stool.</description>
        <time_frame>24 hours (Visit 3 = Day 1)</time_frame>
        <population>Intent-to-treat</population>
        <group_list>
          <group group_id="O1">
            <title>ROSE-010 30 Mcg</title>
            <description>A glucagon-like peptide-1 (GLP-1) analogue. Subjects received a ROSE-010 30 mcg subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.</description>
          </group>
          <group group_id="O2">
            <title>ROSE-010 100 Mcg</title>
            <description>A glucagon-like peptide-1 (GLP-1) analogue. Subjects received a ROSE-010 100 mcg subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.</description>
          </group>
          <group group_id="O3">
            <title>ROSE-010 300 Mcg</title>
            <description>A glucagon-like peptide-1 (GLP-1) analogue. Subjects received a ROSE-010 300 mcg subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Subjects received a matching placebo subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.</description>
          </group>
        </group_list>
        <measure>
          <title>Colonic Transit, Colonic Geometric Center at 24 Hours</title>
          <description>The scintigraphic method is used to measure colonic transit. An isotope is adsorbed on activated charcoal particles and delivered to the colon in a delayed release capsule. Anterior and posterior gamma images are taken hourly. The geometric center (GC) is the weighted average of counts in the different colonic regions. The scale ranges from 1 to 5; a high GC implies faster colonic transit, a GC of 1 implies all isotope is in the ascending colon, and a GC of 5 implies all isotope is in the stool.</description>
          <population>Intent-to-treat</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.39" spread="0.22"/>
                    <measurement group_id="O2" value="2.37" spread="0.41"/>
                    <measurement group_id="O3" value="2.02" spread="0.23"/>
                    <measurement group_id="O4" value="1.76" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change Between Postprandial and Fasting Whole Gastric Volume by Technetium-99m (99mTc)-SPECT Imaging (Gastric Accommodation)</title>
        <description>A noninvasive SPECT method was used to measure gastric volume during fasting and 32 min after a liquid nutritional supplement meal. Subjects reported to the clinic after an overnight fast. 99mTC was giving by an intravenous injection in the forearm. The first fasting scan was obtained, and the study medication was given s.c. After 10 min, a 2nd fasting post medication scan was obtained, and the meal consumed; then two serial postprandial scans were obtained. Each scan required 9-12 min. Tomographic images of the gastric wall were obtained throughout the long axis of the stomach using a dual-head gamma camera that rotates around the body. This allows assessment of the radiolabeled circumference of the gastric wall, rather than the intragastric content. For this outcome measure, the scans for the &quot;fasting volume&quot; and 2 &quot;postprandial volumes&quot; were used. The 2 postprandial (PP) volumes were averaged. Change was calculated as (PP - Fasting = gastric accommodation).</description>
        <time_frame>approximately 1 hour after 99mTC injection, approximately 30 min after liquid meal (Visit 5 = approximately 2-10 days after Visit 4)</time_frame>
        <population>Intent-to-treat</population>
        <group_list>
          <group group_id="O1">
            <title>ROSE-010 30 Mcg</title>
            <description>A glucagon-like peptide-1 (GLP-1) analogue. Subjects received a ROSE-010 30 mcg subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.</description>
          </group>
          <group group_id="O2">
            <title>ROSE-010 100 Mcg</title>
            <description>A glucagon-like peptide-1 (GLP-1) analogue. Subjects received a ROSE-010 100 mcg subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.</description>
          </group>
          <group group_id="O3">
            <title>ROSE-010 300 Mcg</title>
            <description>A glucagon-like peptide-1 (GLP-1) analogue. Subjects received a ROSE-010 300 mcg subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Subjects received a matching placebo subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.</description>
          </group>
        </group_list>
        <measure>
          <title>Change Between Postprandial and Fasting Whole Gastric Volume by Technetium-99m (99mTc)-SPECT Imaging (Gastric Accommodation)</title>
          <description>A noninvasive SPECT method was used to measure gastric volume during fasting and 32 min after a liquid nutritional supplement meal. Subjects reported to the clinic after an overnight fast. 99mTC was giving by an intravenous injection in the forearm. The first fasting scan was obtained, and the study medication was given s.c. After 10 min, a 2nd fasting post medication scan was obtained, and the meal consumed; then two serial postprandial scans were obtained. Each scan required 9-12 min. Tomographic images of the gastric wall were obtained throughout the long axis of the stomach using a dual-head gamma camera that rotates around the body. This allows assessment of the radiolabeled circumference of the gastric wall, rather than the intragastric content. For this outcome measure, the scans for the &quot;fasting volume&quot; and 2 &quot;postprandial volumes&quot; were used. The 2 postprandial (PP) volumes were averaged. Change was calculated as (PP - Fasting = gastric accommodation).</description>
          <population>Intent-to-treat</population>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="532.2" spread="36.6"/>
                    <measurement group_id="O2" value="575.6" spread="19.4"/>
                    <measurement group_id="O3" value="515.2" spread="52.5"/>
                    <measurement group_id="O4" value="532.8" spread="22.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Half Time (t1/2) of Gastric Emptying of Solids Measured by Scintigraphy (Gastric Transit)</title>
        <description>Half time (t1/2) of gastric emptying (GE) of solids is the time for half of the ingested solids or liquids to leave the stomach. The scintigraphy for GE t1/2 was done on Visit 2 (Day 0 of the study), the first day of scintigraphy.</description>
        <time_frame>approximately 2 hours after radiolabeled meal is ingested (Visit 2 = Day 0)</time_frame>
        <population>Intent-to-treat</population>
        <group_list>
          <group group_id="O1">
            <title>ROSE-010 30 Mcg</title>
            <description>A glucagon-like peptide-1 (GLP-1) analogue. Subjects received a ROSE-010 30 mcg subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.</description>
          </group>
          <group group_id="O2">
            <title>ROSE-010 100 Mcg</title>
            <description>A glucagon-like peptide-1 (GLP-1) analogue. Subjects received a ROSE-010 100 mcg subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.</description>
          </group>
          <group group_id="O3">
            <title>ROSE-010 300 Mcg</title>
            <description>A glucagon-like peptide-1 (GLP-1) analogue. Subjects received a ROSE-010 300 mcg subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Subjects received a matching placebo subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.</description>
          </group>
        </group_list>
        <measure>
          <title>Half Time (t1/2) of Gastric Emptying of Solids Measured by Scintigraphy (Gastric Transit)</title>
          <description>Half time (t1/2) of gastric emptying (GE) of solids is the time for half of the ingested solids or liquids to leave the stomach. The scintigraphy for GE t1/2 was done on Visit 2 (Day 0 of the study), the first day of scintigraphy.</description>
          <population>Intent-to-treat</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="151.8" spread="10.4"/>
                    <measurement group_id="O2" value="172.6" spread="7.1"/>
                    <measurement group_id="O3" value="210.7" spread="8.6"/>
                    <measurement group_id="O4" value="136.9" spread="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0075</p_value>
            <method>Dunnett's test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Dunnett's test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Gastric Residual at 2 and 4 Hours Measured by Scintigraphy</title>
        <description>The gastric residual will be calculated as the proportion of isotope remaining in the stomach (at 2 and 4 hours).</description>
        <time_frame>2 hours, 4 hours (Visit 2 = Day 0)</time_frame>
        <population>Intent-to-treat</population>
        <group_list>
          <group group_id="O1">
            <title>ROSE-010 30 Mcg</title>
            <description>A glucagon-like peptide-1 (GLP-1) analogue. Subjects received a ROSE-010 30 mcg subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.</description>
          </group>
          <group group_id="O2">
            <title>ROSE-010 100 Mcg</title>
            <description>A glucagon-like peptide-1 (GLP-1) analogue. Subjects received a ROSE-010 100 mcg subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.</description>
          </group>
          <group group_id="O3">
            <title>ROSE-010 300 Mcg</title>
            <description>A glucagon-like peptide-1 (GLP-1) analogue. Subjects received a ROSE-010 300 mcg subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Subjects received a matching placebo subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.</description>
          </group>
        </group_list>
        <measure>
          <title>Gastric Residual at 2 and 4 Hours Measured by Scintigraphy</title>
          <description>The gastric residual will be calculated as the proportion of isotope remaining in the stomach (at 2 and 4 hours).</description>
          <population>Intent-to-treat</population>
          <units>proportion of isotope in the stomach</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Gastric residual at 2 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.66" spread="0.42"/>
                    <measurement group_id="O2" value="0.76" spread="0.03"/>
                    <measurement group_id="O3" value="0.86" spread="0.03"/>
                    <measurement group_id="O4" value="0.59" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastric residual at 4 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.14" spread="0.03"/>
                    <measurement group_id="O2" value="0.16" spread="0.03"/>
                    <measurement group_id="O3" value="0.30" spread="0.06"/>
                    <measurement group_id="O4" value="0.12" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Colonic Geometric Center at 4 h Measured by Scintigraphy</title>
        <description>The scintigraphic method is used to measure colonic transit. An isotope is adsorbed on activated charcoal particles and delivered to the colon in a delayed release capsule. Anterior and posterior gamma images are taken hourly. The geometric center (GC) is the weighted average of counts in the different colonic regions. The scale ranges from 1 to 5; a high GC implies faster colonic transit, a GC of 1 implies all isotope is in the ascending colon, and a GC of 5 implies all isotope is in the stool. (Note: when there is no radio isotope in the colon (e.g., at 4 hours) the geometric center values are recorded as &quot;zero,&quot; thus the mean values can be less than one.)</description>
        <time_frame>4 hours (Visit 2 = Day 0)</time_frame>
        <population>Intent-to-treat</population>
        <group_list>
          <group group_id="O1">
            <title>ROSE-010 30 Mcg</title>
            <description>A glucagon-like peptide-1 (GLP-1) analogue. Subjects received a ROSE-010 30 mcg subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.</description>
          </group>
          <group group_id="O2">
            <title>ROSE-010 100 Mcg</title>
            <description>A glucagon-like peptide-1 (GLP-1) analogue. Subjects received a ROSE-010 100 mcg subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.</description>
          </group>
          <group group_id="O3">
            <title>ROSE-010 300 Mcg</title>
            <description>A glucagon-like peptide-1 (GLP-1) analogue. Subjects received a ROSE-010 300 mcg subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Subjects received a matching placebo subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.</description>
          </group>
        </group_list>
        <measure>
          <title>Colonic Geometric Center at 4 h Measured by Scintigraphy</title>
          <description>The scintigraphic method is used to measure colonic transit. An isotope is adsorbed on activated charcoal particles and delivered to the colon in a delayed release capsule. Anterior and posterior gamma images are taken hourly. The geometric center (GC) is the weighted average of counts in the different colonic regions. The scale ranges from 1 to 5; a high GC implies faster colonic transit, a GC of 1 implies all isotope is in the ascending colon, and a GC of 5 implies all isotope is in the stool. (Note: when there is no radio isotope in the colon (e.g., at 4 hours) the geometric center values are recorded as &quot;zero,&quot; thus the mean values can be less than one.)</description>
          <population>Intent-to-treat</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.70" spread="0.20"/>
                    <measurement group_id="O2" value="0.47" spread="0.16"/>
                    <measurement group_id="O3" value="0.57" spread="0.17"/>
                    <measurement group_id="O4" value="0.53" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Colonic Filling at 6 h Measured by Scintigraphy</title>
        <description>Percent of the radio-labeled meal that reached the colon at 6 hours, indirectly reflecting small bowel transit time.</description>
        <time_frame>6 hours (Visit 2 = Day 0)</time_frame>
        <population>Intent-to-treat</population>
        <group_list>
          <group group_id="O1">
            <title>ROSE-010 30 Mcg</title>
            <description>A glucagon-like peptide-1 (GLP-1) analogue. Subjects received a ROSE-010 30 mcg subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.</description>
          </group>
          <group group_id="O2">
            <title>ROSE-010 100 Mcg</title>
            <description>A glucagon-like peptide-1 (GLP-1) analogue. Subjects received a ROSE-010 100 mcg subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.</description>
          </group>
          <group group_id="O3">
            <title>ROSE-010 300 Mcg</title>
            <description>A glucagon-like peptide-1 (GLP-1) analogue. Subjects received a ROSE-010 300 mcg subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Subjects received a matching placebo subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.</description>
          </group>
        </group_list>
        <measure>
          <title>Colonic Filling at 6 h Measured by Scintigraphy</title>
          <description>Percent of the radio-labeled meal that reached the colon at 6 hours, indirectly reflecting small bowel transit time.</description>
          <population>Intent-to-treat</population>
          <units>percentage of meal</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.6" spread="7.4"/>
                    <measurement group_id="O2" value="54.4" spread="7.8"/>
                    <measurement group_id="O3" value="48.0" spread="10.0"/>
                    <measurement group_id="O4" value="53.5" spread="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ascending Colon Emptying Half-time (AC t1/2) Measured by Scintigraphy</title>
        <description>Ascending colon emptying half-time will be estimated by power exponential analysis of the proportionate emptying over time of counts from the colon. The primary data for this analysis will be the proportion of decay and depth-corrected counts in the ascending colon on the hourly scans on the first day of transit measurement and the 48 hour data.</description>
        <time_frame>48 hours (Visit 4 = Day 2)</time_frame>
        <population>Intent-to-treat</population>
        <group_list>
          <group group_id="O1">
            <title>ROSE-010 30 Mcg</title>
            <description>A glucagon-like peptide-1 (GLP-1) analogue. Subjects received a ROSE-010 30 mcg subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.</description>
          </group>
          <group group_id="O2">
            <title>ROSE-010 100 Mcg</title>
            <description>A glucagon-like peptide-1 (GLP-1) analogue. Subjects received a ROSE-010 100 mcg subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.</description>
          </group>
          <group group_id="O3">
            <title>ROSE-010 300 Mcg</title>
            <description>A glucagon-like peptide-1 (GLP-1) analogue. Subjects received a ROSE-010 300 mcg subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Subjects received a matching placebo subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.</description>
          </group>
        </group_list>
        <measure>
          <title>Ascending Colon Emptying Half-time (AC t1/2) Measured by Scintigraphy</title>
          <description>Ascending colon emptying half-time will be estimated by power exponential analysis of the proportionate emptying over time of counts from the colon. The primary data for this analysis will be the proportion of decay and depth-corrected counts in the ascending colon on the hourly scans on the first day of transit measurement and the 48 hour data.</description>
          <population>Intent-to-treat</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.5" spread="1.6"/>
                    <measurement group_id="O2" value="14.8" spread="3.7"/>
                    <measurement group_id="O3" value="17.1" spread="4.0"/>
                    <measurement group_id="O4" value="19.3" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Colonic Transit, Colonic Geometric Center at 48 h Measured by Scintigraphy, as Compared to Placebo.</title>
        <description>The scintigraphic method is used to measure colonic transit. An isotope is adsorbed on activated charcoal particles and delivered to the colon in a delayed release capsule. Anterior and posterior gamma images are taken hourly. The geometric center (GC) is the weighted average of counts in the different colonic regions. The scale ranges from 1 to 5; a high GC implies faster colonic transit, a GC of 1 implies all isotope is in the ascending colon, and a GC of 5 implies all isotope is in the stool.</description>
        <time_frame>48 hours (Visit 4 = Day 2)</time_frame>
        <population>Intent-to-treat</population>
        <group_list>
          <group group_id="O1">
            <title>ROSE-010 30 Mcg</title>
            <description>A glucagon-like peptide-1 (GLP-1) analogue. Subjects received a ROSE-010 30 mcg subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.</description>
          </group>
          <group group_id="O2">
            <title>ROSE-010 100 Mcg</title>
            <description>A glucagon-like peptide-1 (GLP-1) analogue. Subjects received a ROSE-010 100 mcg subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.</description>
          </group>
          <group group_id="O3">
            <title>ROSE-010 300 Mcg</title>
            <description>A glucagon-like peptide-1 (GLP-1) analogue. Subjects received a ROSE-010 300 mcg subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Subjects received a matching placebo subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.</description>
          </group>
        </group_list>
        <measure>
          <title>Colonic Transit, Colonic Geometric Center at 48 h Measured by Scintigraphy, as Compared to Placebo.</title>
          <description>The scintigraphic method is used to measure colonic transit. An isotope is adsorbed on activated charcoal particles and delivered to the colon in a delayed release capsule. Anterior and posterior gamma images are taken hourly. The geometric center (GC) is the weighted average of counts in the different colonic regions. The scale ranges from 1 to 5; a high GC implies faster colonic transit, a GC of 1 implies all isotope is in the ascending colon, and a GC of 5 implies all isotope is in the stool.</description>
          <population>Intent-to-treat</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.69" spread="0.23"/>
                    <measurement group_id="O2" value="3.79" spread="0.33"/>
                    <measurement group_id="O3" value="3.36" spread="0.37"/>
                    <measurement group_id="O4" value="2.67" spread="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stool Frequency</title>
        <description>Stool frequency was self reported in a Bowel Pattern Diary. The bowel pattern diary was dispensed at the screening visit, and the completed bowel pattern diary was collected at the completion of the study.</description>
        <time_frame>screening visit (Visit 1), 34 days (Visit 6)</time_frame>
        <population>Intent-to-treat</population>
        <group_list>
          <group group_id="O1">
            <title>ROSE-010 30 Mcg</title>
            <description>A glucagon-like peptide-1 (GLP-1) analogue. Subjects received a ROSE-010 30 mcg subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.</description>
          </group>
          <group group_id="O2">
            <title>ROSE-010 100 Mcg</title>
            <description>A glucagon-like peptide-1 (GLP-1) analogue. Subjects received a ROSE-010 100 mcg subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.</description>
          </group>
          <group group_id="O3">
            <title>ROSE-010 300 Mcg</title>
            <description>A glucagon-like peptide-1 (GLP-1) analogue. Subjects received a ROSE-010 300 mcg subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Subjects received a matching placebo subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.</description>
          </group>
        </group_list>
        <measure>
          <title>Stool Frequency</title>
          <description>Stool frequency was self reported in a Bowel Pattern Diary. The bowel pattern diary was dispensed at the screening visit, and the completed bowel pattern diary was collected at the completion of the study.</description>
          <population>Intent-to-treat</population>
          <units>Stools/day</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.75" spread="0.09"/>
                    <measurement group_id="O2" value="1.13" spread="0.17"/>
                    <measurement group_id="O3" value="0.88" spread="0.15"/>
                    <measurement group_id="O4" value="0.70" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stool Consistency Post Treatment</title>
        <description>The subjects rated their stool consistency using the 7-point Bristol Stool Scale. The Bristol Stool Scale is a medical aid designed to classify the form of human feces into seven categories or types. Types 1 and 2 indicate constipation with 3 and 4 being the &quot;ideal stools&quot; especially the latter, as they are the easiest to defecate, and 5-7 tending towards diarrhea. The Bristol stool form was part of the bowel pattern diary, which was dispensed at the screening visit, and the completed bowel pattern diary was collected at the completion of the study.</description>
        <time_frame>34 days (Visit 6)</time_frame>
        <population>Intent-to-treat</population>
        <group_list>
          <group group_id="O1">
            <title>ROSE-010 30 Mcg</title>
            <description>A glucagon-like peptide-1 (GLP-1) analogue. Subjects received a ROSE-010 30 mcg subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.</description>
          </group>
          <group group_id="O2">
            <title>ROSE-010 100 Mcg</title>
            <description>A glucagon-like peptide-1 (GLP-1) analogue. Subjects received a ROSE-010 100 mcg subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.</description>
          </group>
          <group group_id="O3">
            <title>ROSE-010 300 Mcg</title>
            <description>A glucagon-like peptide-1 (GLP-1) analogue. Subjects received a ROSE-010 300 mcg subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Subjects received a matching placebo subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.</description>
          </group>
        </group_list>
        <measure>
          <title>Stool Consistency Post Treatment</title>
          <description>The subjects rated their stool consistency using the 7-point Bristol Stool Scale. The Bristol Stool Scale is a medical aid designed to classify the form of human feces into seven categories or types. Types 1 and 2 indicate constipation with 3 and 4 being the &quot;ideal stools&quot; especially the latter, as they are the easiest to defecate, and 5-7 tending towards diarrhea. The Bristol stool form was part of the bowel pattern diary, which was dispensed at the screening visit, and the completed bowel pattern diary was collected at the completion of the study.</description>
          <population>Intent-to-treat</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.93" spread="0.33"/>
                    <measurement group_id="O2" value="2.96" spread="0.36"/>
                    <measurement group_id="O3" value="2.93" spread="0.47"/>
                    <measurement group_id="O4" value="3.05" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Subjects were assessed for adverse events at every study visit, approximately over 22 days.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>ROSE-010 30 Mcg</title>
          <description>A glucagon-like peptide-1 (GLP-1) analogue. Subjects received a ROSE-010 30 mcg subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.</description>
        </group>
        <group group_id="E2">
          <title>ROSE-010 100 Mcg</title>
          <description>A glucagon-like peptide-1 (GLP-1) analogue. Subjects received a ROSE-010 100 mcg subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.</description>
        </group>
        <group group_id="E3">
          <title>ROSE-010 300 Mcg</title>
          <description>A glucagon-like peptide-1 (GLP-1) analogue. Subjects received a ROSE-010 300 mcg subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>Subjects received a matching placebo subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="11"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="12"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dry heaving</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Stomach ache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Abdominal cramp</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Bloating</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Drowsiness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Lightheadedness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Michael Camilleri</name_or_title>
      <organization>Mayo Clinic</organization>
      <phone>507-266-2305</phone>
      <email>camilleri.michael@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

